HLN Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 8.37% compared to Haleon Plc's net margin of 16.69%. Haleon Plc's return on equity of 8.91% beat AstraZeneca PLC's return on equity of 22.01%.

Haleon Plc has a consensus price target of $11.72, signalling upside risk potential of 19.25%. On the other hand AstraZeneca PLC has an analysts' consensus of $98.96 which suggests that it could grow by 8.08%. Given that Haleon Plc has higher upside potential than AstraZeneca PLC, analysts believe Haleon Plc is more attractive than AstraZeneca PLC.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.471%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.78%. AstraZeneca PLC offers a yield of 1.71% to investors and pays a quarterly dividend of $0.52 per share. Haleon Plc pays 41.96% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. Haleon Plc's net income of $295.8M is lower than AstraZeneca PLC's net income of $2.5B. Notably, Haleon Plc's price-to-earnings ratio is 22.72x while AstraZeneca PLC's PE ratio is 30.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.14x versus 4.92x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Haleon Plc has a consensus price target of $11.72, signalling upside risk potential of 19.25%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3620.74%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Haleon Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Haleon Plc.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.78%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Haleon Plc's price-to-earnings ratio is 22.72x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.14x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

GSK Plc has a net margin of 8.37% compared to Haleon Plc's net margin of 25.09%. Haleon Plc's return on equity of 8.91% beat GSK Plc's return on equity of 42.84%.

Haleon Plc has a consensus price target of $11.72, signalling upside risk potential of 19.25%. On the other hand GSK Plc has an analysts' consensus of $49.35 which suggests that it could grow by 0.21%. Given that Haleon Plc has higher upside potential than GSK Plc, analysts believe Haleon Plc is more attractive than GSK Plc.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.951%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.78%. GSK Plc offers a yield of 3.4% to investors and pays a quarterly dividend of $0.42 per share. Haleon Plc pays 41.96% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are smaller than GSK Plc quarterly revenues of $11.5B. Haleon Plc's net income of $295.8M is lower than GSK Plc's net income of $2.9B. Notably, Haleon Plc's price-to-earnings ratio is 22.72x while GSK Plc's PE ratio is 14.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.14x versus 2.41x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat NuCana Plc's return on equity of -286.82%.

Haleon Plc has a consensus price target of $11.72, signalling upside risk potential of 19.25%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 574485.64%. Given that NuCana Plc has higher upside potential than Haleon Plc, analysts believe NuCana Plc is more attractive than Haleon Plc.

Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.78%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon Plc quarterly revenues are $3.5B, which are larger than NuCana Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than NuCana Plc's net income of -$378.9K. Notably, Haleon Plc's price-to-earnings ratio is 22.72x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.14x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.